| IDN-6439 |
IDN-6439 |
Preclinical |
Indena |
Head and neck cancer |
Details
|
| Trastuzumab glyco-optimised (Glycotope) |
GT-Mab-7.3-GEX |
Phase Ⅰ |
Glycotope |
Gastric cancer, Breast cancer |
Details
|
| Anti-HER2 small molecule imaging agent (Affibody) |
68GaABY025; ABY-002; ABY-0125; ABY-025 |
Phase Ⅲ |
Affibody |
Breast cancer |
Details
|
| AVA-006 |
AVA-006 |
Phase Not Specified |
Avacta Group, Glythera, Avacta Group, Glythera |
Cancer |
Details
|
| Autologous AdHER2 dendritic cell vaccine (National Cancer Institute) |
|
Phase Ⅰ |
National Cancer Institute |
Solid tumours |
Details
|
| ADCT-502 |
ADCT-502,ADCT 502 |
Phase Ⅰ |
Cancer Research Technology, ADC Therapeutics |
Solid tumours |
Details
|
| Trastuzumab biosimilar (Hualan Biological Engineering) |
|
Phase Ⅲ |
Hualan Biological Engineering |
Metastatic breast cancer |
Details
|
| Trastuzumab biosimilar (BIOCND/Genor Biopharma) |
GB-221,GB221 |
Phase Ⅲ |
Genor Biopharma |
Breast cancer |
Details
|
| Trastuzumab biosimilar (BioIntegrator) |
BI-Mab-03 |
Phase Ⅰ |
BioIntegrator |
Breast cancer |
Details
|
| AU-101 |
AU-101 |
Phase Ⅱ |
Aurora BioPharma |
Breast cancer, Osteosarcoma, Glioblastoma |
Details
|
| RG-6194 |
RG-6194; BTRC-4017A |
Phase Ⅰ |
Roche |
Solid tumours |
Details
|
| Pirotinib Hydrochloride |
KBP-5209,KBP5209 |
Phase Ⅱ |
XuanZhu Pharma |
Non small cell lung cancer (NSCLC), Breast cancer, Lung cancer |
Details
|
| KSP-QRH-E3-IRDye800 |
|
Phase Ⅰ |
University of Michigan |
Cholangiocarcinoma |
Details
|
| HER2p63-71 peptide vaccine (Mie University) |
|
Phase Ⅰ |
Mie University |
Cancer |
Details
|
| MEDI-4276 |
MEDI-4276 |
Phase Ⅰ |
MedImmune |
Gastric cancer, Breast cancer |
Details
|
| RG-6148 |
DHES-0815A; RG-6148 |
Phase Ⅰ |
Roche |
HER2-positive breast cancer |
Details
|
| EX-101 |
EX-101,EX101 |
Preclinical |
ExcelMab |
Gastric cancer, Breast cancer |
Details
|
| Recombinant anti-HER2 domain II humanized monoclonal antibody (Qilu Pharmaceutical) |
|
Phase Ⅰ |
Qilu Pharmaceutical |
Breast cancer |
Details
|
| Mubritinib |
TAK-165,TAK165 |
Phase Ⅰ |
Takeda |
Breast cancer |
Details
|
| Trastuzumab biosimilar (Zhejiang Hisun Pharmaceutical) |
HS-022 |
Preclinical |
Hisun Pharm |
Breast cancer |
Details
|
| Trastuzumab biosimilar (CTTQ Pharma) |
|
Phase Ⅲ |
Chiatai Tianqing (CTTQ) |
Breast cancer |
Details
|
| CP-724714 |
CP-724714 |
Phase Ⅱ |
Pfizer |
Metastatic breast cancer |
Details
|
| 111In-CHxADTPA-trastuzumab (Center for Cancer Research, Leidos Biomedical Research Inc/National Institutes of Health) |
|
Phase Ⅱ |
National Institutes of Health |
Diagnostic agents |
Details
|
| Varlitinib Ditosylate |
ARRY-334543; ARRY-543; ASLAN-001; QBT-01; SPS-4370 |
Phase Ⅲ |
Array BioPharma |
Biliary cancer |
Details
|
| Multiple 4SCAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) |
|
Phase Ⅱ |
Shenzhen Geno-Immune Medical Institute |
Breast cancer |
Details
|
| LCB14-0110 |
LCB14-0110; FS-1502 |
Phase Ⅰ |
LegoChemBio, Fosun Pharma |
Gastric cancer, Breast cancer, Solid tumours |
Details
|
| Anti-HER2 ribozyme (Elan/Sirna) |
|
Phase Ⅰ |
Elan Pharm, Merck |
Breast cancer, Ovarian cancer |
Details
|
| Margetuximab |
MGAH-22,MGAH22 |
BLA Filing |
MacroGenics, Green Cross, Zai Lab |
Gastric cancer, HER2-positive metastatic breast cancer |
Details
|
| Trastuzumab biosimilar (Hanwha Biologics) |
HD-201 |
BLA Filing |
Hanwha Biologics, Prestige BioPharma, Mundipharma |
Gastric cancer, oesophageal cancer, Breast cancer |
Details
|
| GQ-1001 |
GQ-1001 |
Phase Ⅰ |
GeneQuantum Healthcare |
HER2-positive breast cancer |
Details
|
| NJH-395 |
NJH-395,NJH 395,NJH395 |
Phase Ⅰ |
Novartis |
Cancer |
Details
|
| Allitinib Tosylate |
AST-6; ALS-1306; AST-1306 |
Phase Ⅱ |
Shanghai Allist Pharmaceuticals |
Breast cancer, Lung cancer |
Details
|
| PX-1031 (Pharmexa) |
PX-1031; PX-103.1; ME-103.1.1; ME-103 |
Phase Ⅱ |
Pharmexa |
Breast cancer |
Details
|
| trastuzumab biosimilar (Hetero) |
Ado-Trastuzumab biosimilar (Hetero) |
Phase Ⅲ |
Hetero Drugs |
Cancer |
Details
|
| AC-480 |
AC-480; BMS-599626 ,AC480; BMS599626 ,AC 480; BMS 599626 |
Phase Ⅰ |
Ambit biosciences |
Glioma, Solid tumours |
Details
|
| Cancer vaccine (Merck & Co/Vical) |
V-930; V-932,V932,V930 |
Phase Ⅰ |
Merck Sharp & Dohme, Vical |
Non small cell lung cancer (NSCLC), Breast cancer, Colorectal cancer, Ovarian cancer |
Details
|
| MRG-002 |
MRG-002 |
Phase Ⅱ |
Shanghai Miracogen |
Gastric cancer, Breast cancer, Solid tumours |
Details
|
| AIP-303 |
AIP-303 |
Phase Ⅱ |
Advanced Imaging Projects |
HER2-positive breast cancer |
Details
|
| GB-251 |
GB-251,GB251 |
Phase Ⅰ |
Genor Biopharma |
HER2-positive metastatic breast cancer |
Details
|
| Ertumaxomab |
|
Phase Ⅱ |
Trion Pharma, NeoPharm |
Breast cancer |
Details
|
| HER2.taNK |
NK-92/5.28.z |
Phase Ⅰ |
NantKwest |
Glioblastoma |
Details
|
| CUDC-101 |
CUDC-101,CUDC101 |
Phase Ⅰ |
Curis |
Non small cell lung cancer (NSCLC), Gastric cancer, Breast cancer, Hepatocellular carcinoma (HCC), Head and neck cancer |
Details
|
| HER-2/HER-1 vaccine (Ohio State University) |
|
Phase Ⅰ |
Ohio State University |
Solid tumours |
Details
|
| Recombinant human neuregulin-1 |
rhNRG-1 |
BLA Filing |
Zensun, SciClone |
Heart failure, Acute myocardial infarction (AMI) |
Details
|
| SHR-A1201 |
SHR-A1201 |
Phase Ⅰ |
Jiangsu Hengrui Medicine |
HER2-positive metastatic breast cancer |
Details
|
| Larotinib Mesylate |
Z-650 |
Phase Ⅲ |
HEC Pharm |
Esophageal squamous cell carcinoma |
Details
|
| TAK-285 |
TAK-285,TAK285 |
Phase Ⅰ |
Takeda |
Solid tumours |
Details
|
| Trastuzumab biosimilar (Bionovis/The Instituto Vital Brazil) |
|
Phase Not Specified |
Bionovis, The Instituto Vital Brazil |
Gastric cancer, Breast cancer, Metastatic breast cancer |
Details
|
| KSP-910638-G |
KSP-910638-G; KSP-910638G |
Phase Ⅰ |
University of Michigan |
Gastrointestinal cancer |
Details
|
| Pertuzumab biosimilar (Shanghai Henlius Biotech) |
HLX-11,HLX11 |
Phase Ⅰ |
Shanghai Henlius Biotech |
Breast cancer, Metastatic breast cancer |
Details
|
| Pelitinib |
EKB-569; WAY-EKB-569,EKB569,WAY EKB569 |
Phase Ⅱ |
Pfizer |
Non small cell lung cancer (NSCLC), Colorectal neoplasms |
Details
|
| Iodine-131-SGMIB anti-HER2 monoclonal antibody |
131I-SGMIB-anti-HER2-VHH1; [131I]-SGMIB Anti-HER2-VHH1; CAM-H2; Iodine-131-SGMIB-anti-HER2-VHH1 |
Phase Ⅱ |
Camel-IDS |
Breast cancer, Gastroesophageal junction adenocarcinoma |
Details
|
| Anti-HER2 monoclonal antibody-MCC-DM1 conjugate (Shanghai Pharma) |
B-003 (Shanghai Pharma) |
Phase Ⅰ |
Shanghai Pharma, Shanghai Jiaolian |
HER2-positive breast cancer |
Details
|
| DP-303c |
DP-303c,DP303c |
Phase Ⅰ |
Shijiazhuang Zhongqi Pharmaceutical |
HER2-positive advanced breast cancer |
Details
|
| GBR-1302 |
GBR-1302; HBM-9302 |
Phase Ⅱ |
Glenmark Pharmaceuticals, Harbour BioMed |
Breast cancer |
Details
|
| Trastuzumab biosimilar (NeuClone/Serum Institute of India) |
|
Phase Ⅰ |
NeuClone, Serum Institute of India |
Gastric cancer, Breast cancer |
Details
|
| Sapitinib |
AZD-8931 |
Phase Ⅱ |
AstraZeneca |
Colorectal cancer |
Details
|
| ALT-P7 |
HM2-MMAE; ALT-P7 |
Phase Ⅰ |
Alteogen, 3SBio |
Gastric cancer, Breast cancer |
Details
|
| AE-37/GP-2 vaccine |
AE-37 (Generex Biotechnology Corporation) |
Phase Ⅱ |
Generex Biotechnology Corporation |
Prostate cancer, Breast cancer |
Details
|
| KN-026 |
KN-026 |
Phase Ⅱ |
Alphamab |
Gastric cancer, Breast cancer |
Details
|
| BMS-690514 |
BMS-690514,BMS690514 |
Phase Ⅱ |
Bristol-Myers Squibb |
Non small cell lung cancer (NSCLC), Breast cancer |
Details
|
| 14C-labeled poziotinib |
|
Phase Ⅰ |
Spectrum Pharmaceuticals |
Solid tumours |
Details
|
| A-166 |
A-166,A166 |
Phase Ⅱ |
Kelun Pharmaceutical |
Gastric cancer, HER2-positive breast cancer |
Details
|
| HER2(EQ)BBzeta/CD19 T cells (City of Hope) |
|
Phase Ⅰ |
Mustang Bio, City of Hope National Medical Center |
Glioma |
Details
|
| ADXS-31164 |
ADXS31-164; ADXS-31164; ADXS-cHER2; ADXS-HER2 |
Phase Ⅱ |
University of Pennsylvania, Advaxis |
Solid tumours, Osteosarcoma |
Details
|
| Recombinant anti-HER2 humanized monoclonal antibody (Shanghai Institute of Biological Products) |
SIBP-01 |
Phase Ⅲ |
Shanghai Institute of Biological Products |
Breast cancer, Metastatic gastric carcinoma, Metastatic breast cancer |
Details
|
| GB-235 |
GB-235,GB235 |
Phase Ⅰ |
Genor Biopharma |
HER2-positive breast cancer |
Details
|
| Trastuzumab biosimilar (STC Biologics) |
STC-101 |
Phase Ⅰ |
STC Biologics |
Solid tumours |
Details
|
| MP-412 |
AV-412; MP-412,MP412,AV412 |
Phase Ⅱ |
Mitsubishi Tanabe Pharma |
Solid tumours |
Details
|
| Hemay-022 |
Hemay-022 |
Phase Ⅰ |
Tianjin Hemay Biotech, Xia Jiang Hemay Pharmaceutical |
HER2-positive breast cancer |
Details
|
| Recombinant anti-HER2 antibody (Anke Biotech) |
|
Phase Ⅲ |
Anke Biotechnology |
Breast cancer |
Details
|
| Selatinib Ditosilate |
QLNC-120,QLNC120 |
Phase Ⅱ |
Qilu Pharmaceutical, Qilu Antibiotics (Linyi) Pharmaceutical |
Non small cell lung cancer (NSCLC), Gastric cancer, Breast cancer |
Details
|
| Recombinant anti-HER2 antibody-Tub114 |
DX126-262; DAC-001 |
Phase Ⅰ |
Hangzhou DAC Biotech |
HER2-positive breast cancer, Solid tumours |
Details
|
| ICT-140 |
ICT-140 |
Preclinical |
ImmunoCellular Therapeutics |
Ovarian cancer |
Details
|
| AEE-788 |
AEE-788; NVP-AEE-788,AEE788,NVPAEE788 |
Phase Ⅱ |
Novartis |
Glioblastoma multiforme |
Details
|
| TAA-013 |
TAA-013,TAA013; TAA 013 |
Phase Ⅲ |
TOT Biopharm |
HER2-positive breast cancer |
Details
|
| Anti-CD3-anti-HER2-activated T cells |
|
Phase Ⅱ |
TransTarget, Barbara Ann Karmanos Cancer Institute, National Cancer Institute |
Breast cancer |
Details
|
| Trastuzumab biosimilar (Tanvex Biopharma) |
TX-05 |
Phase Ⅲ |
Tanvex BioPharma |
Breast cancer |
Details
|
| SPH-3261 |
SPH-3261 |
IND Filing |
Shanghai Pharma |
Malignancies |
Details
|
| Anti-HER2 antibody toxin conjugate (TopoTarget) |
|
Phase Ⅰ |
Novartis, Topotarget |
Cancer |
Details
|
| Trastuzumab duocarmazine |
SYD-985,SYD985; SYD 985 |
Phase Ⅲ |
Synthon |
Gastric cancer, Breast cancer, Solid tumours |
Details
|
| ETBX-021 |
ETBX-021 |
Phase Ⅱ |
Etubics Corporation, NantBioScience |
Metastatic pancreas cancer |
Details
|
| [89Zr]-Df-Trastuzumab |
|
Phase Ⅰ |
University of Alabama at Birmingham |
Breast cancer |
Details
|
| Multi-epitope HER2 peptide vaccine (Mayo Clinic) |
|
Phase Ⅰ |
Mayo Clinic |
Breast cancer |
Details
|
| AMX-3009 Maleate |
AMX-3009; AMX3009马来酸 |
Phase Ⅰ |
Arromax Pharmatech |
Gastric cancer, HER2-positive breast cancer, Pancreatic cancer |
Details
|
| TT-16 |
TT-16 |
Preclinical |
Tessa Therapeutics |
Head and neck cancer |
Details
|
| Recombinant human ErbB3 fragment vaccine (Zensun) |
rhErbB3-f |
Phase Ⅰ |
Zensun |
Solid tumours |
Details
|
| Tesevatinib |
EXEL-7647; KD-019; KD-020; XL-647,KD019,EXEL7647,KD020,XL647 |
Phase Ⅲ |
Exelixis, Kadmon |
Non small cell lung cancer (NSCLC), Autosomal dominant polycystic kidney disease (ADPKD) |
Details
|
| Trastuzumab biosimilar (United BioPharma) |
UB-921 |
Phase Ⅰ |
United BioPharma |
Breast cancer |
Details
|
| Recombinant anti-HER2 humanized monoclonal antibody-DM1 (Qilu Pharmaceutical) |
|
Phase Ⅰ |
Qilu Pharmaceutical |
Breast cancer |
Details
|
| TPIV-100 (TapImmune) |
TPIV-100 |
Phase Ⅱ |
Mayo Clinic, TapImmune |
Breast cancer |
Details
|
| CIDeCAR |
|
Phase Ⅰ |
Bellicum, National Cancer Institute |
Solid tumours, Osteosarcoma |
Details
|
| IBPM002BZ (Inbiopro Solutions) |
IBPM-002BZ |
Phase Not Specified |
Inbiopro Solutions |
Small cell lung cancer (SCLC), Renal cell carcinoma, Colorectal cancer |
Details
|
| MP-0274 |
CME-114; SPA-28; MP-0274; CME-119; CME-118; CME-115; DARPin-41 |
Phase Ⅰ |
Molecular Partners |
Solid tumours |
Details
|
| XMT-1522 |
TAK-522; XMT-1522,TAK 522 |
Phase Ⅰ |
Mersana Therapeutics, Adimab, Takeda |
Non small cell lung cancer (NSCLC), Gastric cancer, Breast cancer |
Details
|
| anti-HER2 ADC (Pfizer) |
PF-06804103 |
Phase Ⅰ |
Pfizer |
Solid tumours |
Details
|
| Anti-HER2 CAR T-cell therapy (Seattle Children's Hospital) |
|
Phase Ⅰ |
Seattle Children's Research Institute |
Central nervous system tumors |
Details
|
| 99m-Tc labeled anti-HER2 single domain antibody (NanoMab) |
99mTc-NM-02 |
Phase Ⅰ |
NanoMab Technology Ltd |
Breast cancer |
Details
|
| HER2 cancer vaccine (BioLife Science) |
IMU-131; PEV-6A; PEV-6,IMU 131; PEV 6A; PEV 6,IMU131; PEV6A; PEV6 |
Phase Ⅱ |
Pevion Biotech, Imugene, Mymetics Corporation |
Gastric cancer, Esophagus cancer, Breast cancer |
Details
|
| BAT-8001 |
BAT-8001 |
Phase Ⅲ |
Bio-Thera Solutions |
Solid tumours, Metastatic breast cancer |
Details
|
| ARX-788 |
ARX-788 |
Phase Ⅰ |
Ambrx, Zhejiang Medicine |
Solid tumours |
Details
|
| PB-357 |
PB-357 |
Phase Ⅰ |
Pfizer |
Solid tumours |
Details
|
| ACE-1702 |
ACE-1702 |
Phase Ⅰ |
Acepodia |
Solid tumours |
Details
|
| BB-1701 |
BB-1701 |
Phase Ⅰ |
BlissBio |
Solid tumours |
Details
|
| Recombinant anti-HER2 subdomain II humanized monoclonal antibody (Livzon Group) |
LZM-005 |
Phase Ⅰ |
Livzon Group Livzon Pharmaceutical Factory |
HER2-positive metastatic breast cancer, HER2-positive breast cancer |
Details
|
| HLX-22 |
AC-101; HLX-22 |
Phase Ⅰ |
AbClon, Shanghai Henlius Biotech |
Gastric cancer, Breast cancer |
Details
|
| 重组人源化抗HER2单克隆抗体（喜康生物） |
|
IND Filing |
JHL Biotech |
Solid tumours |
Details
|
| IBPM003TZ (Inbiopro Solutions) |
IBPM-003TZ |
Phase Not Specified |
Inbiopro Solutions |
Breast cancer |
Details
|
| HER-2 peptide-expressing DNA vaccine (Karolinska Institute) |
|
Phase Ⅰ |
Karolinska Institutet (KI) |
Cancer |
Details
|
| tgDCC-E1A gene therapy (Targeted Genetics) |
|
Phase Ⅱ |
Targeted Genetics |
Breast cancer, Ovarian cancer, Head and neck cancer |
Details
|
| MVA-BN-HER2 |
PX-1032; PX-103.2 |
Phase Ⅱ |
Pharmexa, Bavarian Nordic |
Breast cancer |
Details
|
| AU-105 |
AU-105 |
Phase Ⅱ |
Aurora BioPharma |
Glioblastoma multiforme |
Details
|
| Trastuzumab biosimilar (EirGenix) |
EG-12014 |
Phase Ⅲ |
EirGenix |
Breast cancer |
Details
|
| DZD-9008 |
DZD-9008,DZD9008 |
Phase Ⅱ |
Dizal (Jiangsu) Pharmaceutical |
Advanced non small cell lung cancer |
Details
|
| BDTX-189 |
BDTX-189,BDTX189 |
Phase Ⅱ |
Black Diamond Therapeutics |
Solid tumours |
Details
|
| SHR-1309 |
SHR-1309,SHR1309 |
Phase Ⅰ |
Jiangsu Hengrui Medicine |
HER2-positive metastatic breast cancer |
Details
|
| PKI-166 |
CGP-75166; PKI-166; PKI-75166 |
Phase Ⅱ |
Novartis |
Solid tumours |
Details
|
| Sirotinib Maleate |
XZP-5491,XZP5491 |
Phase Ⅰ |
XuanZhu Pharma |
Esophageal squamous cell carcinoma, Non small cell lung cancer (NSCLC), Gastric cancer |
Details
|
| Trastuzumab biosimilar |
CMAB-809 |
Phase Ⅰ |
Taizhou Mabtech |
Gastric cancer, Breast cancer |
Details
|
| Recombinant anti-HER2 humanized monoclonal antibody (Shenzhen Main Luck Pharmaceuticals) |
|
Phase Ⅰ |
Shenzhen Main Luck Pharmaceuticals |
Breast cancer |
Details
|
| BVAC-B vaccine (Cellid) |
BVAC-B |
Phase Ⅰ |
Cellid Company |
Gastric cancer |
Details
|
| M-802 |
M-802,M802; M 802 |
Phase Ⅰ |
YZY Bio |
Gastric cancer, HER2-positive breast cancer |
Details
|
| Recombinant anti-HER2 humanized monoclonal antibody complex |
B-002,B002 |
Phase Ⅰ |
Shanghai Pharma |
HER2-positive breast cancer |
Details
|
| Sym-013 |
Sym-013 |
Phase Ⅱ |
Symphogen |
Cancer |
Details
|
| Recombinant humanized anti-EGFR monoclonal antibody (Hisun Pharm/Mabworks Biotech) |
HS627 |
Phase Ⅰ |
Beijing Mabworks Biotech, Hisun Pharm |
Breast cancer |
Details
|
| 212 Pb-trastuzumab |
|
Phase Ⅰ |
Areva Pharmaceuticals, University of Alabama at Birmingham, University of Cincinnati |
Metastatic cancer |
Details
|
| Trastuzumab biosimilar (Gedeon Richter) |
|
Preclinical |
Gedeon Richter, STADA Arzneimittel |
Gastric cancer, Breast cancer |
Details
|
| Pertuzumab biosimilar(SL Pharma/Combio) |
|
Phase Ⅰ |
Combio, Beijing ShuangLu Pharmaceutical |
Breast cancer |
Details
|
| Her-2 vaccine (University of Alabama/Galenica Pharmaceuticals) |
|
Phase Ⅰ |
University of Alabama at Birmingham, Adjuvantys |
Breast cancer |
Details
|
| Trastuzumab biosimilar (BioXpress Therapeutics) |
BX-2318 |
Phase Not Specified |
BioXpress Therapeutics SA |
Breast cancer |
Details
|
| Trastuzumab biosimilar (Alteogen) |
ALT-02; ALT-L2; ALT-LS2 |
Phase Ⅰ |
Alteogen, Cristalia, Qilu Pharmaceutical |
Breast cancer, Metastatic gastric carcinoma, HER2-positive metastatic breast cancer, Gastroesophageal junction adenocarcinoma |
Details
|
| Recombinant HER2 humanized monoclonal antibody -DM1 conjugate (Shanghai CP Guojian Pharmaceutical) |
|
IND Filing |
Shanghai CP Guojian |
Unspecified |
Details
|
| Gancotamab (Merrimack) |
MM-302 |
Phase Ⅲ |
Merrimack, Baxter, Johnson & Johnson |
Breast cancer |
Details
|
| MDX H210 |
|
Phase Ⅱ |
Medarex |
Prostate cancer, Breast cancer |
Details
|
| HER2/neu peptide vaccine (Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium) |
|
Phase Ⅱ |
Fred Hutchinson/University of Washington Cancer Consortium |
HER2-positive breast cancer |
Details
|
| Prolanta(Oncolix) |
|
Phase Ⅰ |
Oncolix |
Fallopian tube cancer, Prostate cancer, Breast cancer, Solid tumours, Peritoneum cancer, Ovarian cancer |
Details
|
| IBI315 |
IBI-315; IBI315 |
Phase Ⅰ |
Innovent Biologics, Hanmi |
Cancer |
Details
|
| HER2-antigen specific cancer vaccine |
HER2-ASCI |
Phase Ⅱ |
GlaxoSmithKline |
Breast cancer |
Details
|
| IDM-1 |
IDM-1; MAK/IDM-1; MDX-210/MAK cells |
Phase Ⅲ |
Takeda |
Ovarian cancer |
Details
|
| Lapatinib/Pazopanib |
|
Phase Ⅲ |
GlaxoSmithKline |
Renal cell carcinoma |
Details
|
| MM-111 |
MM-111 |
Phase Ⅱ |
Merrimack |
Gastric cancer, Esophagus cancer, Breast cancer, Solid tumours |
Details
|
| Canertinib Dihydrochloride |
CI-1033; PD-0183805; PD-183805 ,CI1033, PD 0183805,PD 183805 |
Phase Ⅱ |
Pfizer |
Non small cell lung cancer (NSCLC), Breast cancer, Ovarian cancer, Head and neck cancer |
Details
|
| Cipatinib Tosylate |
SHR-1086 |
Phase Ⅰ |
Hansoh Pharma, Shanghai Pharma |
Breast cancer, Lung cancer |
Details
|
| BMS-986186 |
BMS-986186; FS-102 |
Phase Ⅰ |
F-star, Bristol-Myers Squibb |
Gastric cancer, Breast cancer, Solid tumours |
Details
|
| HER2/neu cancer vaccine (University of Washington/Corixa/GSK) |
|
Phase Ⅱ |
University of Washington, GlaxoSmithKline |
Breast cancer |
Details
|
| AP-32788 |
TAK-788; AP-32788 |
Phase Ⅲ |
Takeda, Millennium Pharmaceutical, Ariad |
Non small cell lung cancer (NSCLC) |
Details
|
| ZW-49 |
ZW-49 |
Phase Ⅰ |
Zymeworks, BeiGene |
Gastric cancer, Breast cancer, Solid tumours |
Details
|
| Zenocutuzumab |
MCLA-128 |
Phase Ⅱ |
Merus |
Non small cell lung cancer (NSCLC), Gastric cancer, Solid tumours, Metastatic breast cancer, Ovarian cancer |
Details
|
| Recombinant anti-HER2 human monoclonal antibody-DM1 (Hisun Pharm/Mabworks Biotech) |
|
Phase Ⅰ |
Beijing Mabworks Biotech, Hisun Pharm |
Breast cancer |
Details
|
| Pertuzumab biosimilar (CTTQ) |
|
Phase Ⅰ |
Chiatai Tianqing (CTTQ) |
HER2-positive metastatic breast cancer |
Details
|
| Autologous-HER2-specific-T-cells |
Autologous-HER2-specific-T-cells |
Phase Ⅰ |
Baylor College of Medicine, Texas Children's Hospital, Methodist Hospital System |
Sarcoma |
Details
|
| TGFBeta-resistant-HER2-EBV-CTLs |
TGFBeta-resistant-HER2-EBV-CTLs |
Phase Ⅰ |
Baylor College of Medicine, Methodist Hospital System |
Malignancies |
Details
|
| TAS-0728 |
TAS-0728; TPC-107 |
Phase Ⅱ |
Taiho Pharma |
Solid tumours |
Details
|
| Tarloxotinib Bromide |
TH-4000; PR-610; SN-33999 |
Phase Ⅱ |
Threshold |
Non small cell lung cancer (NSCLC) |
Details
|
| BCD-147 |
BCD-147 |
Phase Ⅰ |
Biocad |
Unspecified |
Details
|
| VB-7756 (Sesen Bio) |
VB-7756 |
Preclinical |
Viventia Biotech, Sesen Bio |
Cancer |
Details
|
| Bispecific monoclonal antibody 2B1 |
|
Phase Ⅰ |
Chiron |
Cancer |
Details
|
| Epertinib |
S-222611,S222611 |
Phase Ⅱ |
Shionogi |
Solid tumours |
Details
|
| MBS-301 |
MBS-301 |
Phase Ⅰ |
Beijing Mabworks Biotech |
Gastric cancer, Breast cancer, Solid tumours |
Details
|
| MB-103 |
MB-103 |
Phase Ⅰ |
City of Hope National Medical Center, Mustang Bio |
Glioblastoma, Brain metastases |
Details
|
| Breast cancer vaccine HER-2/neu (GlaxoSmithKline) |
|
Phase Ⅱ |
GlaxoSmithKline |
Breast cancer |
Details
|
| HS-10182 |
HS-10182,HS10182 |
Phase Ⅰ |
Hansoh Pharma |
Solid tumours |
Details
|
| MX-402 |
MX-402,MX 402,MX402 |
Phase Ⅰ |
MedVax Technologies |
Gastric cancer |
Details
|
| Lapuleucel-T |
APC-8024; BA-7072; DN-2402 |
Phase Ⅱ |
Dendreon Corporation |
Urogenital cancer |
Details
|
| Zanidatamab |
ZW-25 |
Phase Ⅱ |
Zymeworks, BeiGene |
Fallopian tube cancer, Gllbladder cancer, Gastric cancer, Esophagus cancer, Breast cancer, Colorectal cancer, Ovarian cancer, Cervical carcinoma, Biliary cancer |
Details
|
| Pertuzumab biosimilar (NeuClone) |
|
Preclinical |
NeuClone |
Breast cancer, HER2-positive metastatic breast cancer |
Details
|
| Trastuzumab biosimilar (Dong-A ST/Meiji Seika Pharma) |
DA-3111; DMB-3111 |
Phase Ⅰ |
Dong-A Pharmaceutical, Meiji Seika Pharma |
Gastric cancer, Breast cancer |
Details
|
| Poziotinib |
HM-78136; HM-78136B; NOV1201; NOV-120101 |
Phase Ⅱ |
Hanmi, Luye Pharma, Spectrum Pharmaceuticals |
Non small cell lung cancer (NSCLC), Gastric cancer, Breast cancer, Lung cancer, Head and neck cancer |
Details
|
| Trastuzumab conjugate (BioIntegrator) |
BI-CON-02 |
Phase Ⅰ |
BioIntegrator |
Breast cancer |
Details
|
| HER.CAR-CMV-specific-CTLs |
HER.CAR-CMV-specific-CTLs |
Phase Ⅰ |
Baylor College of Medicine, Methodist Hospital System, Texas Children's Hospital |
Glioblastoma multiforme |
Details
|
| Trastuzumab biosimilar (Shanghai Henlius Biotech) |
HLX-02 |
BLA Filing |
Shanghai Henlius Biotech, Accord Healthcare |
Breast cancer |
Details
|
| Trastuzumab biosimilar (Harbin Pharmaceutical Group) |
|
IND Filing |
Harbin Pharmaceutical Group |
Breast cancer |
Details
|
| GP2 peptide vaccine (Cancer InSight) |
|
Phase Ⅰ |
Cancer Insight |
Breast cancer |
Details
|
| MT-5111 |
MT-5111 |
Phase Ⅰ |
Molecular Templates |
Solid tumours |
Details
|
| Disitamab Vedotin (Yantai Rongchang Biological Engineering) |
RC48-ADC; RC-48; RC-48-ADC |
Phase Ⅲ |
Yantai Rongchang Biological Engineering, Remegen |
Gastric cancer, Urothelial cancer, HER2-positive metastatic breast cancer, Biliary cancer |
Details
|
| Recombinant humanized anti-HER2 antibody (Hisun Pharma) |
|
Phase Ⅲ |
Hisun Pharm |
HER2-positive metastatic breast cancer |
Details
|
| MDX-210 |
MDX-210 |
Phase Ⅱ |
Takeda |
Prostate cancer, Breast cancer, Colorectal cancer, Renal carcinoma |
Details
|
| CP-347589 |
CP-347589 |
Phase Not Specified |
Pfizer |
Cancer |
Details
|
| HER-2/Neu pulsed DC1 vaccine (University of Pennsylvania) |
|
Phase Ⅱ |
University of Pennsylvania, National Cancer Institute |
Breast cancer |
Details
|
A-Z